Intestinal Tuberculosis Treatment and Management

Treatment Regimens

• The American Thoracic Society recommends a standard 6-month regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for the first 2 months, followed by isoniazid and rifampin for 4 months 1, 2
• The Centers for Disease Control and Prevention suggests that ethambutol should be included unless primary isoniazid resistance is documented to be less than 4% in the community 1, 2
• The Infectious Diseases Society of America recommends a two-drug regimen of isoniazid and rifampin only for the continuation phase (months 3-6) 1, 3

Special Populations

• The World Health Organization recommends extended treatment duration of at least 9 months for HIV co-infected patients 1
• The American College of Obstetricians and Gynecologists recommends avoiding streptomycin in pregnant women due to ototoxicity 5

Monitoring and Follow-up

• The Centers for Disease Control and Prevention recommends regular evaluation for symptom improvement, treatment adherence, and drug-related adverse effects 1, 5
• The Infectious Diseases Society of America suggests monitoring liver function tests every 2-4 weeks during treatment due to hepatotoxicity risk with isoniazid and rifampin 5

Directly Observed Therapy (DOT)

• The World Health Organization recommends universal DOT for all TB patients because clinicians cannot predict adherence 3, 4
• The Centers for Disease Control and Prevention suggests that DOT involves a healthcare provider or designated person observing medication ingestion 4

Drug-Resistant Tuberculosis

• The Infectious Diseases Society of America recommends treating isoniazid-resistant TB with 6 months of rifampin, ethambutol, and pyrazinamide 7, 3
• The World Health Organization suggests that rifampin-resistant TB requires a longer regimen (18-24 months) and expert consultation 7, 3

Screening and Prevention

• The American Gastroenterological Association recommends screening for latent TB before anti-TNF therapy with patient history, chest X-ray, tuberculin skin test (TST), and interferon-gamma release assays (IGRA) 8
• The Infectious Diseases Society of America suggests that TST interpretation should consider ≥5 mm induration as positive for latent TB 8